Notable
Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival · Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial
Primary completion pushed from Dec 2030 to Dec 2031
Also in this update: Study completion pushed from Dec 2032 to Dec 2033
Guliz OzgunPhase 3 NCT07338981 Registry history of NCT07338981 on ClinicalTrials.gov (opens the registry)